Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: The present invention generally relates to a method for minimizing the formation of insoluble salts of phenoxy herbicides. The method comprises (1) mixing a compatibility agent, amine salts of phenoxy acid herbicides, and a chemical containing non-amine cations in a aqueous system to form a stable and non-nozzle plugging solution; and (2) application of said stable and non-nozzle plugging solution onto target plants.

Abstract: The invention relates to a method for reducing the concentration of amines and salts thereof, wherein the amines have the general chemical formula I R1R2R3N and the salts have the formula II R1R2R3N—H, wherein the amines and salts thereof exist in aqueous solution or aqueous suspension and are brought into contact with clinoptilolitic or clinoptilolite-containing mixtures. The method itself is suitable for use in food preparation and in the manufacture of foods. The inventive idea of reducing the concentration of amines and salts thereof is also useful in the manufacture of medical products for absorbing and for removing amines from the intestinal tract or the skin area of humans and animals.

Abstract: The present invention relates to azomethine-type direct dyes with a tri-aromatic unit having the following formula (I): and their use for colouring keratin fibres, particularly human keratin fibres such as the hair. The invention also relates to a composition for dyeing keratin fibres comprising, in a suitable medium for dyeing, such direct dyes. Another subject of the present invention is a method for dyeing keratin fibres using said dyeing composition. Finally the present invention also relates to precursors for these direct dyes.

Abstract: The present invention relates to a process for the preparation of (1R,2R)-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol.

Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Abstract: A composition of an oil-soluble ionic detergent that does not contribute metal ions to the composition, and which comprises a quaternary non-metallic pnictogen cation and an organic anion having at least one hydrocarbyl group of sufficient length to impart oil solubility to the detergent, the detergent having a total base number (TBN) to total acid number (TAN) ratio of at least 2:1 imparts ash-free basicity to a lubricant composition.

Abstract: The present invention provides Mannich base derivatives of N,N?-dimethyl secondary diamine polymers including Mannich base derivatives of methylamine-terminated poly-(N-methylazetidine) and Mannich base derivatives of methylamine-terminated poly-(N-methylazacycloheptane). Amine curing agent compositions and amine-epoxy compositions containing Mannich base derivatives of N,N?-dimethyl secondary diamine polymers are also disclosed.

Abstract: A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)] phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states.

Abstract: A process for preparing acyl amide compounds is described, in which a recrystallized o-nitrophenoxy carbonyl compound is hydrogenated with hydrogen gas in the presence of a nickel sponge metal catalyst with ring closure to form a benzoxazine, which is then reacted with an acyl halide to give the corresponding acyl amide compound.

Abstract: A composition of an oil-soluble ionic detergent that does not contribute metal ions to the composition, and which comprises a quaternary non-metallic pnictogen cation and an organic anion having at least one hydrocarbyl group of sufficient length to impart oil solubility to the detergent, the detergent having a total base number (TBN) to total acid number (TAN) ratio of at least 2:1 imparts ash-free basicity to a lubricant composition.

Abstract: Polyisobutenylphenol-containing Mannich adducts are prepared by a) alkylation of a phenol with highly reactive polyisobutene at below about 50° C. in the presence of an alkylation catalyst; b) reaction of the reaction product from a) with formaldehyde, an oligomer or a polymer of formaldehyde and at least one amine which has at least one secondary amino function and no primary amino function, or c) reaction of the reaction product from a) with at least one adduct of at least one amine which has at least one secondary or primary amino function and formaldehyde, an oligomer of formaldehyde, a polymer of formaldehyde or a formaldehyde equivalent, and are used as detergent additives in fuel and lubricant compositions, and additive concentrates, fuel compositions and lubricant compositions contain these Mannich adducts.

Abstract: The present invention aims at provision of a method for inhibiting remnant lipoprotein production and a remnant lipoprotein production inhibitor, which includes administering a compound having a CETP inhibitory activity to an administration subject. The remnant lipoprotein production inhibitor of the present invention contains a compound having a CETP inhibitory activity as an active ingredient.

Abstract: A method for highly efficiently preparing high purity crystals of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]-ethyl]-1,3-propanediol hydrochloride. The method involves dissolving 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol in a mixed solvent comprising a solvent in which its hydrochloride is highly soluble and a solvent in which its hydrochloride is less soluble, to prepare a solution of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol; and then adding hydrochloric acid to the resulting solution with stirring, to crystallize the hydrochloride of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chloro-phenyl]ethyl]-1,3-propanediol.

Abstract: The present invention is to provide a novel rare metal extractant containing a cyclic phenol sulfide derivative of the formula (1) and a method for extractive separation of rare metal(s) using the rare metal extractant with high efficiency.

Abstract: A method for preparing a compound having the following formula (I) by reducing a nitro group of the following formula (III) followed by carrying out an intramolecular dehydration condensation, wherein R2 is hydrogen, alkyl, cycloalkyl, phenyl or a 5- or 6-membered heterocyclic, and X is oxygen, sulfur or nitrogen.

Abstract: The present invention relates to a novel class of tri-aryl compounds, compositions comprising the same and processes for the preparation thereof.

Abstract: The present invention relates to new substituted hydroxyphenylamine based modulators of hormone and/or pigment levels, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The invention relates to compounds of formula (I), wherein R1, R2, R1a, R2a, R3, R4, A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

Abstract: A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states.

Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: The present invention provides Mannich base derivatives of N,N?-dimethyl secondary diamine polymers including Mannich base derivatives of methylamine-terminated poly-(N-methylazetidine) and Mannich base derivatives of methylamine-terminated poly-(N-methylazacycloheptane). Amine curing agent compositions and amine-epoxy compositions containing Mannich base derivatives of N,N?-dimethyl secondary diamine polymers are also disclosed.

Abstract: The invention relates to Mannich bases that can be produced from resorcinol, formaldehyde, and triethylenetetramine and/or tetraethylenepentamine. Also disclosed are a method for the production thereof and the use thereof as hardeners for amine-reactive compounds. The inventive Mannich bases are particularly suitable as hardener components in adhesives.

Abstract: Compounds of formula (I): and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective ?2-adrenoreceptor agonist is indicated, for example asthma or chronic obstructive pulmonary disease (COPD).

Abstract: A novel aryl compound represented by the formula (1) in which the characteristic groups represented by X1 and X2 are different from each other: wherein X1 and X2 are characteristic groups which are different from each other and each of which is selected from the group consisting of a chlorine, bromine or iodine atom, —OSO2Q1, —B(OQ2)2, —Si(OQ3)3, —Sn(Q4)3, Z1 (Z2)m, a metal acetylide group and a terminal acetylene group (where Q represents a hydrocarbon group; Q2 represents a hydrogen atom or a hydrocarbon group; two Q2's may be the same as or different from each other or may together form a ring; Q3 represents a hydrocarbon group and three Q3's may be the same as or different from one another; Q4 represents a hydrocarbon group and three Q4's may be the same as different from one another; Z1 represents a metal atom or a metal ion; Z2 represents a counter anion; and m is an integer of 0 or higher); Ar1 and Ar2 independently represent an arylene group and Ar3 represetns an aryl group, provided that any two

Abstract: A method for preparing a compound having the following formula (I) by reducing a nitro group of the following formula (III) followed by carrying out an intramolecular dehydration condensation, wherein R2 is hydrogen, alkyl, cycloalkyl, phenyl or a 5- or 6-membered heterocyclic, and X is oxygen, sulfur or nitrogen.

Abstract: A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)] phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states.

Abstract: The present invention provides compounds and methods for the inhibition of monoamine uptake in mammals.

Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: N-protected/N-substituted alpha-amino aldehydes, which are useful as pharmaceuticals and pharmaceutical intermediates, can be stored and shipped in a more stable form as N-protected/N-substituted-beta-amino hydroxy sulfonates which can be readily converted back into the aldehyde under mild conditions. The present invention relates to N-protected/N-substituted-beta-amino hydroxy sulfonates and their preparation and use.

Abstract: The 3-aminophenol derivatives of formula (I), or the physiologically compatible, water-soluble salts thereof: wherein R1 represents a group of formula (II) or a group of formula (III): are useful as couplers in hair colorants. Agents for dyeing keratin fibers, especially hair, based on a developer-coupler combination containing these compounds and methods of dyeing using these agents are described.

Abstract: A method for the regioselective ortho-directed nitration of phenolic compounds useful for the preparation of ortho-nitro-phenols according to formula (I) is described.

Abstract: The invention provides novel tetradentate enediyne ligands that are themselves thermally stable, yet react at about room temperature or slightly higher upon addition of metal ions or under photothermal conditions. In another aspect of the invention, a method of treating a disorder in a mammal comprising administering a therapeutically effective amount of a compound or composition is provided. In addition, the free ligand can be delivered to the mammal prior to complexation to metals, such that the ligand is exposed to a metal in the body and forms a metal complex in vivo. Furthermore, a metal complex of the invention can be administered to the mammal such that the complex exchanges the first metal center with another endogenous metal in order to form a second metal complex in vivo. The second metal complex is capable of forming a benzenoid diradical under physiological conditions and/or under photothermal conditions.

Abstract: New ligands and compositions with bridged bis-aromatic ligands are disclosed that catalyze the polymerization of monomers into polymers. These catalysts with metal centers have high performance characteristics, including higher comonomer incorporation into ethylene/olefin copolymers, where such olefins are for example, 1-octene, propylene or styrene. The catalysts also polymerize propylene into isotactic polypropylene.

Abstract: The invention provides for a non-steroidal compound having the formula wherein Re and ′Re are OH, optionally independently etherified or esterified; Z is —CH2— or —CH2CH2—; R1 is H, halogen, CF3, or (1C-4C)alkyl; R2, R3 and R4 are independently H, halogen, —CF3, —OCF3, (1C-8C)Alkyl, hydroxy, (1C-8C)alkyloxy, aryloxy, aryl(1C-8C)alkyl, halo(1C-8C)alkyl, —O(CH2)mX, wherein X is halogen or phenyl and m=2-4; —O(CH2)mNRaRb, —S(CH2)mNRaRb or —(CH2)mNRaRb, wherein m=2-4 and Ra, Rb are independently (1C-8C)alkyl, (2C-8C)alkenyl, (2C-8C)alkynyl, or aryl, optionally substituted with halogen, —CF3, —OCF3, —CN, —NO2, —OH, (1C-8C)alkoxy, aryloxy, carboxyl, (1C-8C)alkylthio, carboxylate, (1C-8C)alkyl, aryl, aryl(1C-8C)alkyl, halo(1C-8C)alkyl or Ra and Rb form a 3-8 membered ring structure, optionally substituted with halogen, —CF3, —OCF3, —CN, —NO2, hydroxy, hydroxy(1C-4C)a

Abstract: Larrea tridentata and Ambrosia deltoidea are shown to produce compounds that inhibit replication of HIV. The compounds can be extracted by differential fractionation and by counter-current chromatographic methods described herein. Extracts prepared from L. tridentata and A. deltoidea are found to be effective in inhibiting viral replication. The extracts from L. tridentata have been characterized and found to contain tricyclic lignans. The extracts can be administered to subjects for treatment of viral infection.

Abstract: Quaternary salts having a double helix structure are prepared by the reaction of dihydroxyaromatic compound, preferably a bisphenol, with an alkali metal hydroxide and a quaternary salt, such as a tetraalkylammonium or hexaalkylguanidinium chloride. The quaternary salts and their alkaline hydrolysis products are useful as catalysts in various reactions, including imide formation from bisphenol salts and halo- or nitro-substituted phthalimides and redistribution and equilibration of polycarbonates.

Abstract: Novel alkene intermediates useful in the preparation of 1,2-dioxetanes.

Abstract: A novel anti-active oxygen agent which comprises as active ingredient an amino acid derivative represented by the following general formula (I): ##STR1## wherein Ar represents a 2-hydroxyphenyl, 2-hydroxy-1-naphthyl or pyridyl group, and one or more of the hydrogen atoms attached to the aromatic ring of these groups may be substituted with a halogen atom, or an alkyl, hydroxyl, hydroxyalkyl, nitro, alkoxyl or carboxyl group; R represents the side chain of an amino acid; X represents --CH.sub.2 --NH-- or --CH.dbd.N--; Y represents a hydrogen atom, --COOR.sup.1, --SO.sub.3 H, --CON(R.sup.2)R.sup.3, --CONHCH(R.sup.5)COOR.sup.4 or --CH.sub.2 OH (where each of R.sup.1 to R.sup.4 represents a hydrogen atom or an alkyl group, and R.sup.5 represents the side chain of an amino acid); and n represents an integer of 0 or 1;or its salt,and which inhibits generation of active oxygen species, has a high safety and can be prepared at relatively low costs.

Abstract: The present invention relates to a process for producing (E)-alkoxyiminoacetamide compounds useful as agricultural fungicides and a process for producing (E)-hydroxyiminoacetamide compounds useful as intermediates for producing them. The present invention also relates to an industrial process for producing (E)-methoxyiminoacetamide compounds useful as agricultural fungicides. This process is advantageous in terms of the cost, safety and the like.

Abstract: Compounds of the formula, ##STR1## in which one of R.sub.30 and R.sub.40 represents a substituted phenylalkyl group and the other of R.sub.30 and R.sub.40 represents hydrogen or halogen, and R.sub.50 and R.sub.60 each independently represent hydrogen or alkyl.The compounds of the invention are useful for the treatment or prophylaxis of renal failure or cardiovascular disease.

Abstract: The ethanolamine salt of N-nitrosophenylhydroxylamine ("NPHA") is effective as a polymerization inhibitor for ethylenically unsaturated monomers. The ethanolamine salt can be prepared by reacting ethanolamine with the ammonium salt of NPHA. Advantageously, the ethanolamine salt is soluble in high concentrations in water and a variety of polar organic solvents.

Abstract: Prepare novel .alpha.-aminoalkylphenols by contacting an .alpha.-alkenylphenol and an amine under reaction conditions.

Abstract: A novel sulfone compound represented by the general formula (I) ##STR1## wherein R.sup.1 is cyclohexyl, phenyl; or a phenyl substituted with a group selected from nitro, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and halogen; R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are respectively hydrogen, halogen, cyano or carbonyl, wherein R.sup.1 and R.sup.2 may form an o-phenylene or an o-phenylene substituted with at least one group selected from nitro C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy and halogen; X is oxygen or methylkene; Y is -(CH.sub.2).sub.n --, wherein n is an integer of 0, 5 or 6, or ##STR2## wherein m is an integer 1-3; R.sup.6 is hydrogen, C.sub.1 -C.sub.3 alkyl, .omega.-alkylaminoalkyl, wherein each alkyl has 1-3 carbon atoms, or .omega.-dialkylaminoalkyl, wherein each alkyl has 1-3 carbon atoms; R.sup.7 is hydrogen or C.sub.1 -C.sub.3 alkyl; and R.sup.6 and R.sup.7 may form a ring together with N, or ##STR3## wherein R.sup.8 is hydrogen, C.sub.1 -C.sub.

Abstract: A Process is described for lining the inner surfaces of pipes or pipe sections using the Insituform method by pressing a tubular flexible laminate made up of an essentially liquid-impermeable membrane and a fibrous layer which has been impregnated with a binder which is not as yet fully cured with the face with the binder against the inner surface of the pipe by means of liquid pressure in such a way that the laminate takes on the shape of the inner surface of the pipe and the binder becomes fully cured in the state, forming a firmly adhering internal lining. The binder used according to the invention in this process contains(a) a curing agent which is a salt of one or more (poly)amines having at least one tertiary nitrogen atom and one or more aromtic polyols or one or more aliphatically substituted phenols, the aliphatic radical having at least 9 carbon atoms, and(b) a liquid epoxy resin or a liquid mixture of epoxy resins and can, if desired, also contain(c) further additives.

Abstract: A fluorine-containing quaternary ammonium compound of the formula: ##STR1## wherein R.sub.f is a fluorine-containing straight or branched aliphatic hydrocarbon or polyether group, R.sub.1, R.sub.2 and R.sub.3 are each a C.sub.1 -C.sub.21 straight or branched alkyl, hydroxyalkyl or alkenyl group or a substituted or unsubstituted aryl or aralkyl group, R.sub.4 is a hydrogen atom or a acyl group, X.sup.- is an anion and n is an integer of 1 to 3, having a capability of reducing the surface tension of water and the interfacial tension between water and oil.

Abstract: A salt of 6-sec.-butyl-2,4-dinitrophenol and choline of the formula ##STR1## having selective herbicidal activity.

Abstract: New dopamine derivatives are disclosed, which are tertiary amines and which exhibit especially dopaminergic properties, and which have the formula ##STR1## wherein R.sub.1 signifies an alkyl group containing at least 4 carbon atoms, a cycloalkyl alkyl group, a cycloalkyl group or a phenylalkyl group and R.sub.2 signifies an alkyl group, a cycloalkyl alkyl group, a cycloalkyl group, or a phenylalkyl group.

Abstract: A catalyst and accelerator for an epoxy system which consists of a halogeisphenate of a catalytically active tertiary amine and which is obtained in a solid form practically water insoluble and odor free but which nevertheless possess the catalytic activity of the tertiary amine. The application describes the proportion of the catalyst by reacting an aqueous suspension of the halogenobisphenol with the tertiary amine, the proportion of epoxy resin systems containing the catalyst and the epoxy resin systems thus formed.

Abstract: The invention is accomplished by the formation at the site of use of the radioactive amine of the invention which is then injected immediately into the mammal for diagnostic purposes. The compounds of the invention are as follows: ##STR1## In the above compound, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently any straight or branched alkyl of between 1 and about 10 carbons; n may be between 1 and about 20.In the invention, the radio labeling of the invention compound is accomplished immediately prior to use of the radio labeled material. The compounds of the invention when boiled for about 15 minutes with iodine-123, a radioactive material, undergo a substitution of radioactive for non-radioactive iodine such that the compound becomes labeled and suitable for use. The compound itself, prior to radio labeling, is storage stable.